Design, synthesis, and biomedical evaluation of Ag/Cu bimetallic MOFs for controlled drug delivery and synergistic therapeutic applications.

Cancer and antibiotic resistance are major global health concerns due to high mortality rates, frequent treatment failures, and the development of resistance to conventional therapies. In the proposed research, a multifunctional silver/copper (Ag/Cu) bimetallic metal-organic framework (MOF) is described as a biomedical platform. Its integrity was ensured by structural characterization, and in vitro tests on MCF-7 breast cancer cells showed that the Ag/Cu MOF had intrinsic antitumor activity, with cytotoxicity and cell viability of 33.9% and 66.1%, respectively. The suggested MOF had PCM and CUR drug-loading capacities of 57.7% and 28.9%, respectively, with full release of PCM in 48 h and partial release of 40-60% of CUR in three days. Besides, the Ag/Cu MOF showed potent antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli), antifungal activity against Aspergillus flavus and Aspergillus niger, and high antioxidant activity. These results indicate that the Ag/Cu MOF can serve as a useful multifunctional nanoplatform for drug delivery and other biomedical applications.